New anticoagulant treatments to protect against stroke in atrial fibrillation

Heart

Volumn 98, Issue 18, 2012, Pages 1341-1347

  Potpara, Tatjana S ^a,b   Lip, Gregory Y H ^c   Apostolakis, Stavros ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; PHENPROCOUMON; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVERSION; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; STROKE; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84865189210     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301841     Document Type: Review

References (71)

1. Prystowsky EN. The history of atrial fibrillation: the last 100 years. J Cardiovasc Electrophysiol 2008;19 :575-82. (Pubitemid 351832294)
2. Lewis T. Auricular fibrillation. In: Clinical Disorders of the Heart Beat: A Handbook for Practitioners and Students. 3rd edn. New York: Paul B Hoeber (Copyright London, England: Shaw and Sons), 1916:82-98.
3. Merskey C, Drapkin A. Analytical review: anticoagulant therapy. Blood 1965;25:567-96.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
5. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36:1115-19. (Pubitemid 40803473)
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. (Pubitemid 351650486)
7. Ogilvie IM, Newton N, Welner SA, et al . Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123:638-45.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al The RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
9. Connolly SJ, Eikelboom J, Joyner C, et al AVERROES Seering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
10. Granger CB, Alexander JH, McMurray JJ, et al ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
11. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
12. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91.
13. Connolly SJ, Pogue J, Hart RG, et al. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
14. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968-77.
15. Matchar DB, Jacobson A, Dolor R, et al THINRS Executive Committee and Site Investigators. Effect home testing international normalised ratio clinical events. N Engl J Med 2010;363:1608-20.
16. Anderson JL, Horne BD, Stevens SM, et al. A Randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for Individualizing Warfarin dosing: CoumaGen-II. Circulation 2012;125:1997-2005.
17. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a metaanalysis. Arch Intern Med 2012;178:623-31.
18. Huhtakangas J, Tetri S, Juvela S, et al . Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 2011;42:2431-5.
19. Camm JA, Kirchof P, Lip GY, et al European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation. The Task Force for the management of atrial fibrillation of the European society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
20. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation - friend or foe? Thromb Haemost 2010;104:45-8.
21. Keogh C, Wallace E, Dillon C, et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106:528-38.
22. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish atrial fibrillation cohort study. Eur Heart J. Published Online First: 13 January 2012. doi:10.1093/eurheartj/ehr488
23. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72.
24. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
25. Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012;5:319-26.
26. Lip GY, Andreotti F, Fauchier L, et al; European heart rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a position document from the European heart rhythm Association [EHRA], endorsed by the European society of Cardiology [ESC] Working group on thrombosis. Thromb Haemost 2011;106:997-1011.
27. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49.
28. Nieuwlaat R, Capucci A, Lip GY, et al; On behalf the Euro heart Survey investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro heart Survey on atrial fibrillation. Eur Heart J 2006;27:3018-26. (Pubitemid 44963431)
29. Glader EL, Sjolander M, Erikosson M, et al. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010;41:397-401.
30. Marinigh R, Lip GY, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010;56:827-37.
31. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57:1339-48.
32. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104 :49-60.
33. De Caterina R, Husted S, Wallentin L, et al. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes: ESC Working group on thrombosis-Task Force on anticoagulants in heart disease position Paper. J Am Coll Cardiol 2012;59:1413-25.
34. Ezekowitz MD, Wallentin L, Connolly SJ, et al RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010;122:2246-53.
35. Wallentin L, Yusuf S, Ezekowitz MD, et al RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
36. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6.
37. Diener HC, Connolly SJ, Ezekowitz MD, et al RE-LY Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-63.
38. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
39. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94.
40. Lawrence J, Pogue J, Synhorst D, et al AVERROES Steering Committee and Investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012;11:225-31.
41. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15.
42. Connolly SJ, Ezekowitz MD, Yusuf S, et al Randomized Evaluation of Long-term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-6.
43. Artang R, Rome E, Vidaillet H. Dabigatran and myocardial infarction, drug or class effect. Meta-analysis of randomized trials with oral direct thrombin inhibitors. J Am Coll Cardiol 2012;59:E571.
44. Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010;123:785-9.
45. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
46. Fukuda T, Honda Y, Kamisato C, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012;107:253-9.
47. Kaatz S, Kouides PA, Garcia DA, et al . Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(Suppl 1):S141-5.
48. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulation activity. Thromb Haemost 2010;103:1116-27.
49. Wann LS, Curtis AB, Ellenbogen KA, et al Am Coll Cardiol Foundation/American Heart Assoc Task Force. ACCF/AHA/ HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American heart Association Task Force on practice guidelines. Circulation 2011;123:1144-50.
50. Skanes AC, Healey JS, Cairns JA, et al Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the canadian cardiovascular society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36.
51. Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modeling analysis based on a nationwide cohort study. Thromb Haemost 2012;107:584-9.
52. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010;104:1099-105.
53. Go AS, Fang MC, Udaltsova N, et al For the ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. Circulation 2009;119 :1363-9.
54. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107:838-47.
55. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.
56. Lip GY, Larsen TB, Skjøth F, et al. Indirect comparison of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. Published Online First: 8 May 2012. doi:10.1016/j.jacc.2012.03.019
57. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59:1168-74.
58. Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012;23:264-8.
59. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. A consensus document of the European society of Cardiology Working group on thrombosis, endorsed by the European heart rhythm Association (EHRA) and the European Association of percutaneous cardiovascular interventions (EAPCI). Thromb Haemost 2010;103:13-28.
60. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North- American perspective. Thromb Haemost 2011;106:572-84.
61. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011;106:569-71.
62. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
63. Alexander JH, Lopes RD, James S, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
64. Pengo V, Crippa L, Falanga A, et al Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011;106:868-76.
65. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
66. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123 :2562-70.
67. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19.
68. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42.
69. Landmesser U, Holmes DR. Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 2012;33:698-704.
70. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman left atrial appendage system for Embolic Protection in patients with AF (PROTECT AF) clinical trial and the continued Access registry. Circulation 2011;123:417-24.
71. Reddy V, Neuzil P, Miller MA, et al. First formal analysis of the ASA Plavix Registry (ASAP): Watchman left atrial appendage closure in atrial fibrillation patients with contraindication to oral anticoagulation. Heart Rhythm Society 2012 Scientific Sessions; May 11, 2012; Boston, MA. Abstract LB02-2. http://www.abstractsonline.com